Lonza Group AG (LZAGY) Q4 2023 Earnings Call Transcript Summary
Lonza Group AG (LZAGY) Q4 2023 Earnings Call Transcript Summary
The following is a summary of the Lonza Group AG (LZAGY) Q4 2023 Earnings Call Transcript:
以下是隆沙集團股份公司（LZAGY）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Lonza reported group sales of CHF 6.7 billion in 2023, showing a growth of 10.9%.
Profits stood at CHF 655 million in 2023, declining by 46% year-on-year, primarily due to divestment gains and impairment losses.
The core EBITDA remained steady at CHF 2 billion, resulting in a margin of 29.8%.
The free cash flow for 2023 was CHF 329 million, backed by net working capital improvements and CapEx prioritization.
Net debt rose to CHF 1.1 billion due to investments in organic growth and the share buyback program.
A proposed dividend increase of 14% to CHF 4 per share is planned for 2023.
龍沙報告稱，2023年集團銷售額爲67億瑞士法郎，增長10.9％。
2023年利潤爲6.55億瑞士法郎，同比下降46％，這主要是由於撤資收益和減值損失。
核心息稅折舊攤銷前利潤穩定在20億瑞士法郎，利潤率爲29.8％。
2023年的自由現金流爲3.29億瑞士法郎，這得到了淨營運資本改善和資本支出優先排序的支持。
由於對有機增長和股票回購計劃的投資，淨負債增至11億瑞士法郎。
計劃在2023年將股息增加14％，至每股4瑞士法郎。
Business Progress:
業務進展：
The company observed strong performance in Biologics and Small Molecules divisions, which generated over 70% of the revenue with a margin exceeding 30% each.
About 130 new CDMO customers and 350 new clinical and commercial programs were signed in 2023, indicating significant market operations progress.
The company foresees high capacity utilization over the next five years, led by sustained manufacturing services demand and successful Phase I drug candidates.
Sustainability efforts are being bolstered, with reductions in emission, energy, and water intensity accomplished.
For 2024, the company expects high single-digit underlying sales growth and a core EBITDA margin in the high 20s (27% - 29%), driven by sturdy commercial CDMO business performance and anticipated recovery in Capsules & Health Ingredients.
There are expansion plans for growth investments in Europe and Americas, and an improved core EBITDA margin within the 32% - 33% range by 2028 is projected.
Jean-Marc Hyvert is proposed to be the new Chairman of Lonza, as decided at the forthcoming AGM in May.
該公司觀察到生物製劑和小分子部門的強勁表現，這些部門創造了70％以上的收入，利潤率各超過30％。
2023年簽署了約130個新的CDMO客戶和350個新的臨床和商業項目，這表明市場運營取得了重大進展。
該公司預計，在持續的製造服務需求和成功的I期候選藥物的帶動下，未來五年的產能利用率將很高。
可持續發展工作正在得到加強，排放、能源和水強度均已降低。
該公司預計，2024年的基礎銷售額將實現較高的個位數增長，核心息稅折舊攤銷前利潤率將達到20年代的最高水平（27％-29％），這要歸因於穩健的商業CDMO業務表現以及膠囊和健康成分的預期復甦。
歐洲和美洲都有增長投資的擴張計劃，預計到2028年，核心息稅折舊攤銷前利潤率將提高到32％至33％的範圍內。
根據即將於5月舉行的股東周年大會的決定，提議讓-馬克·海弗特出任隆沙的新任董事長。
More detailed: LONZA GROUP AG UNSP ADR EACH REP 0.1 ORD IR
Tips: This article is generated by AI and the accuracy of the content can not be fully guaranteed. For more and comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由AI生成，無法完全保證內容的準確性。欲了解更多全面的詳情，請訪問投資者關係網站。本文僅供投資者參考，不提供任何指導或建議建議。
譯文內容由第三人軟體翻譯。